- Both holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (B-TUEP) are safe, minimally invasive surgical options for treating benign prostatic hyperplasia (BPH) in patients at high risk of bleeding because of anticoagulation (AC) or antiplatelet (AP) therapy.
Why this matters
- A significant number of patients who require surgery for BPH are receiving either AC or AP therapy.
- Researchers analyzed the health records of patients who underwent HoLEP and B-TUEP and were receiving AC or AP therapy or neither therapy (N=438; 100% white; HoLEP, 67.6%; B-TUEP, 32.4%).
- Funding: None.
- Patients in the HoLEP group with either AC or AP therapy required longer catheter maintenance and hospital stays (all P≤.01).
- Patients in the B-TUEP group with either AC or AP therapy had longer hospital stays (P=.03) and more complications (P=.001).
- Operative times and rates of postoperative complications were similar regardless of AC or AP therapy.
- Postoperative hemoglobin drop and 2-month International Prostate Symptoms Scores were similar regardless of therapy or surgical technique.
- The study was retrospective and did not assess complications or functional outcomes >60 days after surgery.